Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLORA: GLPG1690 in Idiopathic Pulmonary Fibrosis
NCT02738801Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF), sponsored by Galapagos NV. Started Mar 2016; status: completed.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02738801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738801.